Journal profile · MEDICINE, RESEARCH & EXPERIMENTAL
Biomedical Research and Therapy
ISSN 2198-4093 · BiomedPress
Biomedical Research and Therapy: CAS Zone 4 · Medicine (2025 upgraded edition); fully open access; APC charged, amount not published; median 155 days to acceptance (55 articles, last 24 months); 89 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Biomedical Research and Therapy is published by BiomedPress and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Mesenchymal stem cell research, Tissue Engineering and Regenerative Medicine and Cancer Cells and Metastasis, together about 31.8% of its articles. Its main subfields are Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Biomedical Research and Therapy (Online ISSN 2198-4093) publishes 12 peer-reviewed issues each year, covering a wide range of biomedical and clinical sciences. Unlike many open-access journals, which charge authors for publication while providing free reader access, Biomedical Research and Therapy does not require fees for subscription, submission, processing, publication, or color image reproduction. Recognized internationally, this journal is committed to disseminating high-quality research in an open-access format, emphasizing basic, translational, and clinical studies on molecular therapeutics and cellular therapies. It includes research involving animal models and clinical trials. The rigorous peer-review process ensures that only scientifically, technically, and ethically sound articles adhering to standard reporting guidelines are published. The journal’s editorial policies are in strict alignment with standards set by the International Committee of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), and the Committee on Publication Ethics (COPE), upholding the highest principles of publication ethics. Biomedical Research and Therapy (Online ISSN 2198-4093) is the official journal of the VNUHCM-US Stem Cell Institute, Ho Chi Minh City, Viet Nam. This journal is managed and published by Biomedpress on behalf of the owners, the VNUHCM-US Stem Cell Institute, Ho Chi Minh City, Viet Nam.
From the journal's Aims & Scope
Research area (LetPub): MEDICINE, RESEARCH & EXPERIMENTAL
Editor-in-chief Phuc Van PhamPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Mesenchymal stem cell researchMedicine18.6%
- Tissue Engineering and Regenerative MedicineMedicine8.3%
- Cancer Cells and MetastasisMedicine5%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.1%
- Liver Disease Diagnosis and TreatmentMedicine4.1%
- Reproductive Biology and FertilityMedicine3.9%
- Immune Cell Function and InteractionImmunology and Microbiology3.9%
- CAR-T cell therapy researchMedicine3.7%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Medicine, Research & Experimental | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbasePublisher website
Other: Asean Citation Index, Google Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 1.1LetPub ·
- SJR 2026-06
- 0.23LetPub ·
- SNIP 2026-06
- 0.23LetPub ·
- h-index
- 28OpenAlex ·
- i10-index
- 140OpenAlex ·
- 2-year mean citedness
- 1.14OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 97.92%LetPub ·
Volume
- Articles per year
- 91LetPub ·
Articles by year OpenAlex count · 1,023 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 63 | 63 | 5 |
| 2025 | 89 | 89 | 141 |
| 2024 | 93 | 93 | 133 |
| 2023 | 67 | 67 | 121 |
| 2022 | 67 | 67 | 270 |
| 2021 | 62 | 62 | 352 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
155 daysMedian, submission to acceptance · P25–P75 80 days – 181 days
- Acceptance to online
- median 18 days (55 articles)
- Submission to online
- median 174 days
- Sample
- 55 articles with submission and acceptance dates (185 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | Yes, amount not published | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- original researchOriginal Research Structure-Based Identification of Multi-Target Phytochemical Inhibitors from Garuga pinnata and Mitragyna speciosa Targeting the AXL Kinase an…Length not stated
- reviewReview Vitamin D Receptor Gene Polymorphisms in Type 1, Type 2, and Gestational Diabetes Mellitus: A Comprehensive Meta-Analysis and Meta-Regression of 154 Stud…Length not stated
Policy excerpts from the journal's websitePublication ethics, Peer review
- Publication ethics
Human and animal rights and informed consent policy Model summary
Human and animal rights, and Informed Consent
Source ↗Publisher website ·- Peer review
Editorial policies align with ICMJE, WAME, and COPE standards. Model summary
The journal’s editorial policies are in strict alignment with standards set by the International Committee of Medical Journal Editors (ICMJE), the World Association of Medical Editors (WAME), and the Committee on Publication Ethics (COPE), upholding the highest principles of publication ethics.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- BiomedPress
- ISSN
- 2198-4093
- Society / sponsor
- VNUHCM-US Stem Cell Institute
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
FAQ
Frequently asked questions about Biomedical Research and Therapy
What CAS zone is Biomedical Research and Therapy in?
In the 2025 upgraded edition of the CAS Journal Ranking, Biomedical Research and Therapy is in Zone 4 of Medicine, and in Zone 4 of the minor category Medicine, Research & Experimental. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Biomedical Research and Therapy?
Based on the dates recorded on 55 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 155 days (interquartile range 80–181 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Biomedical Research and Therapy?
According to LetPub and DOAJ records, Biomedical Research and Therapy is indexed in ESCI and Scopus. The journal's website also lists Embase; that list has not been checked against each database.
Is Biomedical Research and Therapy open access, and what is the APC?
Biomedical Research and Therapy is a fully open-access journal. APC charged, amount not published.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .